Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Up 380.1% in May

Posted by ABMN Staff on May 29th, 2026

Silexion Therapeutics Corp (NASDAQ:SLXN – Get Free Report) saw a large growth in short interest during the month of May. As of May 15th, there was short interest totaling 159,027 shares, a growth of 380.1% from the April 30th total of 33,126 shares. Based on an average daily trading volume, of 476,377 shares, the days-to-cover ratio is presently 0.3 days. Currently, 5.0% of the company’s shares are sold short.

Silexion Therapeutics Stock Performance

Silexion Therapeutics stock opened at $0.43 on Friday. The stock’s 50 day simple moving average is $8.59 and its two-hundred day simple moving average is $17.01. The stock has a market cap of $1.79 million, a price-to-earnings ratio of -0.05 and a beta of -0.29. Silexion Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $22.36.

Silexion Therapeutics (NASDAQ:SLXN – Get Free Report) last posted its quarterly earnings data on Friday, May 15th. The company reported ($8.50) earnings per share for the quarter, beating the consensus estimate of ($12.90) by $4.40. On average, analysts predict that Silexion Therapeutics will post -4.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a report on Wednesday, March 18th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Read Our Latest Analysis on Silexion Therapeutics

About Silexion Therapeutics

(Get Free Report)

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.